These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19443407)

  • 1. Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer.
    Tarle M; Spajic B; Kraljic I; Kusic Z
    Anticancer Res; 2009 May; 29(5):1797-801. PubMed ID: 19443407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early diagnosis of prostate cancer in finasteride treated BPH patients.
    Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
    Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    Mellon JK
    Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of finasteride on risk of prostate cancer: how little we really know.
    Rubin MA; Kantoff PW
    J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is tumour grade applicable to finasteride-treated prostate cancer?].
    Molinié V; Ruffion A; Allory Y; Leroy X; Cochand Priollet B; Paraf F; de la Taille A
    Prog Urol; 2005 Jun; 15(3):387-91. PubMed ID: 16097140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
    Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
    J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia].
    de la Taille A
    Prog Urol; 2008 Apr; 18 Suppl 3():S53-7. PubMed ID: 18455085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
    Zitella A; Berruti A; Destefanis P; Mengozzi G; Torta M; Ceruti C; Casetta G; Mosca A; Greco A; Rolle L; Aimo G; Aroasio E; Tizzani A; Dogliotti L; Fontana D;
    Clin Chim Acta; 2007 Feb; 377(1-2):103-7. PubMed ID: 17034778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost of prostate cancer chemoprevention: a decision analysis model.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer prevention and finasteride.
    D'Amico AV; Barry MJ
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
    Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
    Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
    J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.